Paediatric Strategy Forums

Upcoming Forums

13th Paediatric Strategy Forum for diffuse midline gliomas

8-9 May 2024

SickKids, Toronto


Submit your Expression of Interest today!

14th Paediatric Strategy Forum ON Novel ways to target and enhance efficiency of anti-GD2 therapies

Autumn 2024

Europe

About the Forums


Paediatric Strategy Forums are multi-stakeholder meetings in which strategies regarding new drug development are discussed. Each Forum focuses on either a given paediatric malignancy or the development of a class of compounds with regards to their mechanism of action. These scientific meetings are aimed at facilitating prioritisation in order to better meet the needs of patients and to increase feasibility of paediatric developments.
Suggest new topics
What?
 

A multi-stakeholder Forum where all Stakeholders share information and discuss the strategy of new drug development with regards to their Mechanism of Action (MoA) to address unmet medical needs in a transparent scientific discussion

When?
 

Q1/ Midst/ Q4 every year

Where?
 

2 live Paediatric Strategy Forums – 1 in Europe & 1 in US

 

1 Virtual Paediatric Strategy Forum

Why?
 

To share information, to facilitate the development of innovative medicines and ultimately their introduction into the standard-of-care of children with malignancies

Agreement by all involved (industry and academia) based on scientific arguments

Which product, based on current evidence, is considered to have the highest potential to address unmet medical needs 

The sequence in which other available (or emerging) products should be developed or deferred. So that  as soon as a development is completed (either due to futility or efficacy) others are already prepared for evaluation

Engage regulatory agencies in a consolidated effort early in development

Monitoring changes in regulatory submissions and approvals both in Europe and the US (changing from adult-condition based waivers to scientifically and medically relevant waivers)

Publish results publicly via summaries and manuscripts

Oversight Committee

The ACCELERATE Oversight Committee is a multi-stakeholder committee which is responsible for the choice of topics and proposing dates for the Paediatric Strategy Forums. They identify 2-3 representatives from relevant international cooperative trial groups from both sides of the Atlantic for the preparation of each Forum. The Oversight Committee also monitors the impact of the Forums.

ACCELERATE Steering Commitee
Global Paediatric Cancer Community
Regulators
Dominik Karres
Koen Norga
Alberto Pappo
Patient Advocates
12TH Paediatric Strategy Forum for CDK4/6, CDK 7 and CDK 9 Inhibitors

26-27 October 2023, Amsterdam

11TH Paediatric Strategy Forum for PI3K, mTOR and AKT inhibitors

3-4 April 2023, Boston

10TH Paediatric Strategy Forum for DNA Damage Pathway Inhibitors

27-28 October 2022, Amsterdam


Scientific manuscript: HERE

9TH PAEDIATRIC STRATEGY FORUM FOR MEDICINAL PRODUCT DEVELOPMENT IN MAPK PATHWAY INHIBITORS

28 March & 29 March 2022

Virtual

  • Scientific manuscript: HERE
8TH PAEDIATRIC STRATEGY FORUM FOR MEDICINAL PRODUCT DEVELOPMENT OF MULTI-TARGETED KINASE INHIBITORS IN BONE SARCOMA

30 November & 1 December 2021,

Virtual

  • Scientific manuscript: HERE
7TH PAEDIATRIC STRATEGY FORUM FOR MEDICINAL PRODUCT DEVELOPMENT OF CAR T-CELLS IN CHILDREN AND ADOLESCENTS

25-27 May 2021, Virtual


  • Scientific manuscript: HERE
6th Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies

13-14 January 2021, Virtual

  • Scientific manuscript: HERE
5th Paediatric Strategy Forum for Medicinal Product Development of Epigenetic Modifiers in Children and Adolescents

23-24 January 2020, Philadelphia

  • Public summary: HERE
  • Scientific manuscript: HERE
4th Paediatric Strategy Forum for Medicinal Product Development for Acute Myeloid Leukaemia in Children and Adolescents

11-12 April 2019, Rotterdam

  • Public summary: HERE
  • Scientific manuscript: HERE
3rd Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients

5-6 September 2018, EMA, London

  • Public summary: HERE
  • Scientific manuscript: HERE
2nd Paediatric Strategy Forum for Medicinal product development for mature B-cell malignancies in children

13-14 November 2017, EMA, London

  • Public summary: HERE
  • Scientific manuscript: HERE
1st Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies

30-31 January 2017, EMA, London

  • Public summary: HERE